BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1220 related articles for article (PubMed ID: 18349295)

  • 1. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Anderson LA; Cantwell MM; Watson RG; Johnston BT; Murphy SJ; Ferguson HR; McGuigan J; Comber H; Reynolds JV; Murray LJ
    Gastroenterology; 2009 Mar; 136(3):799-805. PubMed ID: 19162028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
    Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
    Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Mulholland HG; Cantwell MM; Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; McGuigan J; Reynolds JV; Comber H; Murray LJ
    Cancer Causes Control; 2009 Apr; 20(3):279-88. PubMed ID: 18839322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
    Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
    J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Vaninetti NM; Geldenhuys L; Porter GA; Risch H; Hainaut P; Guernsey DL; Casson AG
    Mol Carcinog; 2008 Apr; 47(4):275-85. PubMed ID: 17849424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma.
    Moons LM; Kuipers EJ; Rygiel AM; Groothuismink AZ; Geldof H; Bode WA; Krishnadath KK; Bergman JJ; van Vliet AH; Siersema PD; Kusters JG
    Am J Gastroenterol; 2007 Nov; 102(11):2373-9. PubMed ID: 17581270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
    Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important?
    Gough MD; Ackroyd R; Majeed AW; Bird NC
    Am J Gastroenterol; 2005 May; 100(5):1012-8. PubMed ID: 15842572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma.
    van Lieshout EM; Roelofs HM; Dekker S; Mulder CJ; Wobbes T; Jansen JB; Peters WH
    Cancer Res; 1999 Feb; 59(3):586-9. PubMed ID: 9973204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
    Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
    J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma.
    Murphy SJ; Hughes AE; Patterson CC; Anderson LA; Watson RG; Johnston BT; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Carcinogenesis; 2007 Jun; 28(6):1323-8. PubMed ID: 17277236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barrett's esophagus and medications that relax the lower esophageal sphincter.
    Corley DA; Levin TR; Habel LA; Buffler PA
    Am J Gastroenterol; 2006 May; 101(5):937-44. PubMed ID: 16573773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma.
    Casson AG; Zheng Z; Porter GA; Guernsey DL
    Cancer Detect Prev; 2006; 30(5):423-31. PubMed ID: 17064856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
    Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
    Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.